Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Follicle-stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection in Idiopathic Hypogonadotropin Hypogonadism

NCT06561594 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06561594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06561594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Follicle-stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection in Idiopathic Hypogonadotropin Hypogonadism
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 20, 2024
Completion date
December 23, 2026
Enrollment
60 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic hypogonadotropic hypogonadism